drugset / Trial / NCT06563115
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of (PEG)-BHD1028
RandomizedSequentialDouble-blindTreatment
Summary
Adiponectin has been known to play critical roles in various physio-regulatory processes, and adiponectin deficiency may contribute to insulin resistance. (PEG)-BHD1028 was developed as an agonist of adiponectin receptors. This first-in-human study evaluates the safety, tolerability, pharmacokinetics, and pharmacodynamics of (PEG)-BHD1028 in healthy overweight/obese subjects with insulin resistance.
Timeline
- Start
- 2022-04-18
- Primary completion
- 2024-04-23
- Completion
- 2024-06-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | (PEG)-BHD1028 | Peptide | 4 ug/kg | Subcutaneous |
| Subject | (PEG)-BHD1028 | Peptide | 8 ug/kg | Subcutaneous |
| Subject | (PEG)-BHD1028 | Peptide | 16 ug/kg | Subcutaneous |
| Subject | (PEG)-BHD1028 | Peptide | 32 ug/kg | Subcutaneous |
| Subject | (PEG)-BHD1028 | Peptide | 64 ug/kg | Subcutaneous |
Indications
No indication recorded.